Compare Fidelity National Information Servcs Inc (FIS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs TG Therapeutics Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.03 (market cap $17.71B), while TG Therapeutics Inc trades at $54.85 (market cap $8.16B). The key difference: Fidelity National Information Servcs Inc is far larger — about 2.2× TG Therapeutics Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and TG Therapeutics Inc for 16 Days on average.
| FIS | TGTX | |
|---|---|---|
Market Cap | $17.71B | $8.16B |
Volume | 9,047,825 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $68.57 | $59.06 |
52-Week Low | $32.44 | $26.94 |
Typical Hold Time | 88 Days | 16 Days |
Enterprise Value | $38.22B | $8.37B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.19, up 1.09% with bearish technical signals but strong fundamentals including a low P/E of 5.27 and net income margin of 27.65%. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss. The company demonstrates business momentum with multiple core banking wins and product launches, including embedded banking platform and cloud modernization initiatives announced in September 2026.
FIS presents a compelling value opportunity with attractive valuation metrics and improving profitability, though technical indicators suggest near-term pressure. The 37% upside to consensus price target of $47.15 and strong analyst support (57% buy ratings) indicate Wall Street optimism, balanced by debt concerns and competitive fintech landscape requiring careful monitoring.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
